Regarding the anti-tumor efficacy of CK1 inhibition, for example, it has been shown that CK1δ/ε inhibitors with low nanomolar IC50s demonstrated efficacy in vitro and in preclinical in vivo models of breast cancer (e.g., SR-3029 [46]). The gene discussed is CSNK1A1; the disease is neoplasm.